OX40 agonists are undergoing evaluation in solid tumors and hematologic malignancies, with several studies exploring combination therapies involving OX40 and other immune checkpoint inhibitors (e.g., PD-1, CTLA-4, 4-1BB). This evidence concerns the gene TNFRSF4 and hematologic disorder.